ARL4C stabilized by AKT/mTOR pathway promotes the invasion of PTEN‐deficient primary human glioblastoma

Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) deficiency in primary human glioblastoma (GBM) is associated with increased invasiveness and poor prognosis with unknown mechanisms. Therefore, how loss of PTEN promotes GBM progression remains to be elucidated. Herein, we identified that ADP‐ribosylation factor like‐4C (ARL4C) was highly expressed in PTEN‐deficient human GBM cells and tissues. Mechanistically, loss of PTEN stabilized ARL4C protein due to AKT/mTOR pathway‐mediated inhibition of ARL4C ubiquitination. Functionally, ARL4C enhanced the progression of GBM cells in vitro and in vivo. Moreover, microarray profiling and GST pull‐down assay identified that ARL4C accelerated tumor progression via RAC1‐mediated filopodium formation. Importantly, targeting PTEN potently inhibited GBM tumor progression in vitro and in vivo, whereas overexpression of ARL4C reversed the tumor progression impaired by PTEN overexpression. Clinically, analyses with patients' specimens validated a negative correlation between PTEN and ARL4C expression. Elevated ARL4C expression but PTEN deficiency in tumor was associated with poorer disease‐free survival and overall survival of GBM patients. Taken together, ARL4C is critical for PTEN‐deficient GBM progression and acts as a novel prognostic biomarker and a potential therapeutic candidate. Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

[1]  T. Gupta,et al.  MGMT gene promoter methylation and its correlation with clinicopathological parameters in glioblastomas , 2018, Neurology India.

[2]  S. Courtneidge,et al.  Invadosomes are coming: new insights into function and disease relevance , 2018, The FEBS journal.

[3]  Tsai-Shin Chiang,et al.  ADP-ribosylation factor–like 4C binding to filamin-A modulates filopodium formation and cell migration , 2017, Molecular biology of the cell.

[4]  X. Bian,et al.  Autophagy-induced KDR/VEGFR-2 activation promotes the formation of vasculogenic mimicry by glioma stem cells , 2017, Autophagy.

[5]  X. Bian,et al.  High‐mobility group box 1 released by autophagic cancer‐associated fibroblasts maintains the stemness of luminal breast cancer cells , 2017, The Journal of pathology.

[6]  Y. Kwon,et al.  Crosstalk and Interplay between the Ubiquitin-Proteasome System and Autophagy , 2017, Molecules and cells.

[7]  R. DePinho,et al.  Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer , 2017, Nature.

[8]  Y. Kondo,et al.  Epigenetic upregulation of ARL4C, due to DNA hypomethylation in the 3'-untranslated region, promotes tumorigenesis of lung squamous cell carcinoma , 2016, Oncotarget.

[9]  M. Nakasone,et al.  Ubiquitination Accomplished: E1 and E2 Enzymes Were Not Necessary. , 2016, Molecular cell.

[10]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[11]  Jean-Marc Schwartz,et al.  A MAPK-Driven Feedback Loop Suppresses Rac Activity to Promote RhoA-Driven Cancer Cell Invasion , 2016, PLoS Comput. Biol..

[12]  J. M. May,et al.  Intracellular Ascorbate Prevents Endothelial Barrier Permeabilization by Thrombin* , 2015, The Journal of Biological Chemistry.

[13]  You-hong Cui,et al.  miR-663 Suppresses Oncogenic Function of CXCR4 in Glioblastoma , 2015, Clinical Cancer Research.

[14]  Trevor Hastie,et al.  Clinically Relevant Molecular Subtypes in Leiomyosarcoma , 2015, Clinical Cancer Research.

[15]  N. Biglia,et al.  ADP-ribosylation factor-like 4C (ARL4C), a novel ovarian cancer metastasis suppressor, identified by integrated genomics. , 2015, American journal of translational research.

[16]  S. Heiland,et al.  Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma , 2015, Oncotarget.

[17]  L. Klein-Hitpass,et al.  High-Resolution Genomic Analysis Does Not Qualify Atypical Plexus Papilloma as a Separate Entity Among Choroid Plexus Tumors , 2015, Journal of neuropathology and experimental neurology.

[18]  S. Matsumoto,et al.  Arl4c expression in colorectal and lung cancers promotes tumorigenesis and may represent a novel therapeutic target , 2014, Oncogene.

[19]  Ivan Dikic,et al.  Ubiquitination in disease pathogenesis and treatment , 2014, Nature Medicine.

[20]  M. Ishii,et al.  A combination of Wnt and growth factor signaling induces Arl4c expression to form epithelial tubular structures , 2014, The EMBO journal.

[21]  You-hong Cui,et al.  Primate-Specific miR-663 Functions as a Tumor Suppressor by Targeting PIK3CD and Predicts the Prognosis of Human Glioblastoma , 2014, Clinical Cancer Research.

[22]  K. Black,et al.  Loss of PTEN Is Not Associated with Poor Survival in Newly Diagnosed Glioblastoma Patients of the Temozolomide Era , 2012, PloS one.

[23]  N. Lemke,et al.  PTEN augments SPARC suppression of proliferation and inhibits SPARC-induced migration by suppressing SHC-RAF-ERK and AKT signaling. , 2010, Neuro-oncology.

[24]  A. Balmain,et al.  Guidelines for the welfare and use of animals in cancer research , 2010, British Journal of Cancer.

[25]  D. Koul.  PTEN Signaling pathways in glioblastoma , 2008, Cancer biology & therapy.

[26]  C. James,et al.  PTEN Loss Does Not Predict for Response to RAD001 (Everolimus) in a Glioblastoma Orthotopic Xenograft Test Panel , 2008, Clinical Cancer Research.

[27]  C. James,et al.  Increased expression of the glioma-associated antigen ARF4L after loss of the tumor suppressor PTEN. Laboratory investigation. , 2008, Journal of neurosurgery.

[28]  B. Eipper,et al.  Arf6 recruits the Rac GEF Kalirin to the plasma membrane facilitating Rac activation , 2007, BMC Cell Biology.

[29]  S. Hahn,et al.  Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir. , 2007, Cancer research.

[30]  S. Munro,et al.  The Arl4 Family of Small G Proteins Can Recruit the Cytohesin Arf6 Exchange Factors to the Plasma Membrane , 2007, Current Biology.

[31]  Thomas D. Wu,et al.  Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. , 2006, Cancer cell.

[32]  Koji Yoshimoto,et al.  Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. , 2005, The New England journal of medicine.

[33]  C. Burd,et al.  Arf-like GTPases: not so Arf-like after all. , 2004, Trends in cell biology.

[34]  D. Rimm,et al.  X-Tile , 2004, Clinical Cancer Research.

[35]  Ming Tan,et al.  PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. , 2004, Cancer cell.

[36]  G. Mills,et al.  Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors , 2003, Oncogene.

[37]  M. Shigemori,et al.  Recognition of ADP-ribosylation factor 4-like by HLA-A2-restricted and tumor-reactive cytotoxic T lymphocytes from patients with brain tumors. , 2002, Tissue antigens.

[38]  P. Roux,et al.  Regulation of Cdc42‐mediated morphological effects: a novel function for p53 , 2002, The EMBO journal.

[39]  A. Merlo,et al.  PTEN-independent induction of caspase-mediated cell death and reduced invasion by the focal adhesion targeting domain (FAT) in human astrocytic brain tumors which highly express focal adhesion kinase (FAK). , 2001, Cancer research.

[40]  E. Holland,et al.  Glioblastoma multiforme: the terminator. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[41]  A. Goldberg,et al.  Proteasome inhibitors: valuable new tools for cell biologists. , 1998, Trends in cell biology.

[42]  D. Louis,et al.  Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end? , 2013, Nature Reviews Clinical Oncology.